Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/26/2020 06/29/2020 06/30/2020 07/01/2020 07/02/2020 Date
43.5(c) 43.16(c) 42.81(c) 42.71(c) 42.51(c) Last
1 644 445 775 960 1 545 896 1 043 973 529 928 Volume
-0.09% -0.78% -0.81% -0.23% -0.47% Change
More quotes
Financials (USD)
Sales 2020 1 668 M - -
Net income 2020 261 M - -
Net Debt 2020 950 M - -
P/E ratio 2020 35,5x
Yield 2020 -
Sales 2021 1 725 M - -
Net income 2021 283 M - -
Net Debt 2021 627 M - -
P/E ratio 2021 32,3x
Yield 2021 -
Capitalization 9 884 M 9 884 M -
EV / Sales 2020 6,50x
EV / Sales 2021 6,09x
Nbr of Employees 5 100
Free-Float 97,2%
More Financials
Company
Qiagen N.V. is one of the world's leaders in designing, manufacturing, and marketing chemical products for the isolation, purification, and manipulation of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). In 2019, the group developed more than 500 consumable products and automated solutions through its 35 production sites worldwide. Net sales break down geographically as follows: the United States (43.5%),... 
More about the company
Surperformance© ratings of Qiagen N.V.
Trading Rating : Investor Rating :
More Ratings
Latest news on QIAGEN N.V.
07/03QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
07/02Elizabeth Tallett Joins Moderna's Board of Directors
AQ
06/30QIAGEN N : shareholders approve all agenda items related to acquisition by Therm..
PU
06/24QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/23QIAGEN N : provides information on potential capital gain from its minority inve..
PU
06/23QIAGEN N.V. : QIAGEN provides information on potential capital gain from its min..
EQ
06/23QIAGEN NV : Warburg Research reaffirms its Neutral rating
MD
06/22QIAGEN N : Announces Plans to Release Preliminary Q2 2020 Results
BU
06/19QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/15QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/08QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/04QIAGEN NV : Downgraded from Neutral to Sell by Independant Research
MD
06/02QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
05/29QIAGEN NV : DZ Bank reiterates its Neutral rating
MD
05/28QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
More news
News in other languages on QIAGEN N.V.
08:55aUSA: Les valeurs à suivre à Wall Street
07:09aUSA: Les valeurs à suivre à Wall Street
06:18aWALL STREET STOCK EXCHANGE : USA-Les valeurs à suivre à Wall Street (actualisé)
07/03QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
07/03Aktien Frankfurt Schluss: Gewinnbringende Woche endet mit Atempause
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | QGEN | NL0012169213 | MarketScreener
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 41,17 $
Last Close Price 43,26 $
Spread / Highest target 15,6%
Spread / Average Target -4,84%
Spread / Lowest Target -28,3%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Sven Håkan Björklund Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.25.77%9 712
LONZA GROUP45.13%40 295
CELLTRION, INC.68.78%34 505
SEATTLE GENETICS, INC.47.93%29 259
IQVIA HOLDINGS INC.-8.41%27 025
INCYTE CORPORATION21.93%23 144